The HIV-1 envelope glycoprotein surface subunit gp120 is an attractive target for molecular intervention. This is because anti-HIV-1 gp120 neutralizing antibodies display the potential ability to inhibit HIV-1 infection. The present investigation describes the construction of a genetically engineered single chain antibody (scFv102) against HIV-1 gp120, its expression and functional evaluation. The parental hybridoma cell line (102) produces an immunoglobulin directed against the conserved CD4-binding region of gp120. cDNAs encoding the variable regions of the heavy (V H ) and light (V L ) chains were prepared by reverse transcription PCR and linked together with an oligonucleotide encoding a linker peptide (Gly 4 Ser) 3 to produce a single chain antibody gene. The resulting DNA construct was cloned into a prokaryotic expression vector (pET28) and recombinant scFv102 was expressed in Eserichia coli as an insoluble protein. The denatured scFv102 was refolded and purified by immobilized metal ion affinity chromatography. Purified scFv102 had the same specificity as the intact IgG in immuno-blotting assays and immuno-fluorescence (IF) detection, but ELISA analyses demonstrated the affinity of scFv102 to be 5-fold lower than that of the parental monoclonal antibody. In neutralization assays, scFv102 at concentrations lower than 40 m g/ml exhibited efficient interference with viral replication and inhibition of viral infection (90%) across a range of primary isolates of subtype B HIV-1. These results suggest that the constructed anti-HIV-1 gp120 scFv102 has good biological activity and can potentially be used for in vitro diagnostic and in vivo therapeutic applications.
Introduction
Human immunodeficiency virus type I (HIV-1) is the aetiological agent of AIDS. The viral envelope glycoprotein (encoded by the env gene), including external glycoprotein gp120 and trans-membrane protein gp41, plays a critical role in the viral entry processes that leads to infection [1] . HIV-1 infects target cells through sequential binding of the envelope glycoprotein via cellular receptors, coreceptor interactions including specific protein-protein interactions and conformational changes [2, 3] . Binding of the HIV-1 envelope glycoprotein initiates a series of conformational changes that are at the heart of the fusion mechanism needed to initiate viral entry. Anti-envelope antibodies demonstrate great potential for both detection of HIV-1 infection and inhibition of viral replication [4, 5] . These antibodies can mediate neutralization of free virions or block the virus from binding to host cells. Neutralizing antibodies directed against the conserved and accessible regions of the envelope spike may therefore interfere with viral attachment and Env conformational steps of viral invasion, thereby inhibiting target cell infection [6] .
Traditionally, antibodies have been obtained only from immunized animals; however, recent progress in molecular biology has made it possible to produce monoclonal antibody (mAb) fragments from bacterial or yeast cells [7] . The antigenic variable regions of the heavy and light chains (V H and V L , respectively) are essential for the recognition of antigens. Antibody single-chain variable region fragments (scFv) containing V H and V L DNA joined by a flexible linker sequence have great potential in antibody-based therapeutics [8] . Recombinant scFvs. prepared from antibody-secreting hybridoma cells, produced by genetic engineering, have properties that mAbs or their functional fragments prepared by proteolysis [Fab and F(ab)' 2 ] do not have [9] . scFv can combine with inactive molecules within cells to inhibit HIV-I replication [10, 11] . Additionally, scFv can neutralize the phenomenon of Fc-or Fc-receptor-dependent enhancement of HIV-I infection [12] . When coupled to ribosome inactivating proteins, scFv forms chimeric immunotoxins which can specifically kill HIV-1 infected cells and halt the spread of infection. Such immunotoxins, combined with multidrug cocktails, can effectively reduce viral reservoirs and improve the therapeutic effects of highly active antiretroviral therapy (HAART) [13] .
We have previously produced a neutralizing murine mAb specific for an antigenic domain overlapping the CD4 binding site, a poorly immunogenic epitope, which contains major viral neutralizing antigenic sites and is relatively conserved among various viral strains. Although this mAb can participate in neutralization of the HIV-1 infection, there are many restrictions on using primitive forms of the murine antibody in antiviral immunotherapy. Here, we report the screening of an anti-HIV-1 gp120 single chain variable gene fragment from mAb-secreting hybridoma cells, its expression in a prokaryotic expression systems and the analysis of its biological activity.
Materials and methods

Plasmid, cells and media
A murine hybridoma secreting mAb 102 (specific for the HIV-1 gp120 CD4 binding site) had previously been screened and identified in our laboratory. An IgG (Kd 6·3 ¥ 10 -8 M) from hybridoma 102(IgG2a) was purified using a Protein A Sepharose column (Amersham Pharmacia Biotech, Uppsala, Sweden) and then dialysed in PBS (pH 8·0). Primary isolated subtypes B HIV-1 (Chinese epidemic strains, SF2) and MT4 cells (a human T-lymphoid cell line transformed by human T-cell lymphotropic virus type 1 [14] ) were obtained from the Chinese AIDS Reference Laboratory. Hela-Env cells (HIV-1 gp120 gene transfected cell lines which could stably express HIV-1 gp120) were preserved in our laboratory. All cells were grown on RPMI 1640 medium supplemented with 10% fetal calf serum, 2 mM l -glutamine, penicillin (10 IU/ml), and streptomycin (10 m g/ml) with 5% CO 2 at 37 ∞ C. E. coli BL21 (DE3) cells, transformed with the prokaryotic vector pET28 (T7 RNA polymerase gene under lac UV5 promoter control, a T7/lac promoter and T7 transcription terminator, plus an optional C-terminal His-Tag sequence for protein purification) for protein expression, were acquired from Novagen Biotech (Madison, USA). Competent E. coli cells JM101 were used for gene transformation. Horseradish peroxidase (HRP)-conjugated sheep anti-mouse IgG, HRP-conjugated goat anti-human IgG, alkaline phosphatase(AP)-conjugated goat anti-mouse mAb and anti-His-Tag mAb were purchased from Qiagen Biotech (Hilden, Germany).
Cloning of V H and V L 102 genes by reverse transcription PCR
Cytoplasmic RNA was purified from 3 ¥ 10 6 hybridoma cells using TRIZOL reagent (Gibco, NY, USA) using the method provided by the manufacturer. Cellular mRNA was isolated from the total RNA preparation by binding to oligo (dT) 25 linked magnetic beads using a Dynabeads mRNA kit according to the manufacturer's instructions (Promega Biotech, Madison, USA). Isolated mRNA from freshly subcloned hybridoma 102 cells was used as a template and first-strand cDNA was synthesized using Moloney murine leukaemia virus reverse transcriptase (RT). For PCR amplification of the heavy and light chain genes (V H and V L ), pairs of primers which were designed and synthesized according to the degenerate sequences in the conserved hypervariable complementarity defining regions (provided in the mouse scFv module recombinant phage antibody system, from Amersham Pharmacia Biotech, Uppsala, Sweden) were used. Amplification was accomplished using the standard reaction conditions described in the manufacturer's protocol. The amplified fragments were checked by 1% agarose-gel electrophoresis and the gene products were ligated to the TA cloning vector pGEM-T (Promega Biotech, Madison, USA). The DNA sequence was determined using an automated sequencer.
Construction of the scFv expression vector
The V H and V L fragments from the first PCR reaction were isolated separately and purified on an agarose gel. The purified Fv fragments were then combined in a second recombinant PCR reaction. Overlapping PCR primers with a synthetic linker were used to join the V H and V L regions. The V H and V L chains were amplified and assembled with the linker-encoding DNA fragment to produce the scFv gene segment via overlap extension methods (SOE) [15] .
For construction of the gene expression vector, scFv 102 was re-amplified with a pairs of primers P1: (5 ¢ -CATGC CATGGGACCAGGTCAAGCTGCAGGAG-3 ¢ ) and P2: (5 ¢ -CCCAAGCTTTTATTTCCAGCTTGGTC-3 ¢ ). The resultant PCR fragments were inserted into the prokaryotic expression vector pET28a at the Nco I and Hind III sites. This generated the recombinant plasmid pET-scFv, in which the C-terminal domain of scFv was fused with a His-tag for improved purification and immune identification.
Expression and purification of recombinant scFv
E. coli BL21 (DE3) was transformed with pET-scFv, and the transformant cells were cultivated at 37 ∞ C in 250 ml flasks containing 50 ml of LB medium supplemented with 50 m g of ampicillin per ml. When the culture reached an optical density of 0·7 (OD600), protein expression was induced by adding isopropyl-thio-b -D-galactopyranoside (IPTG) to a final concentration of 1·0 mM. After 4 h incubation at 37 ∞ C, bacteria were harvested by centrifugation at 6000 g for 10 min at 4 ∞ C. Total cellular protein was analysed by SDS-PAGE and western-blotting. Anti-His-tag mAb was used for immunodetection of the expressed foreign proteins. For determination of the mature forms of the expression products, the collected cells were disrupted by sonication for 1-2 min at maximum output. After centrifugation at 10 000 g for 10 min at 4 ∞ C, the supernatant fluid (soluble-protein fraction) and the pellet (inclusion-body fraction) were analysed by SDS-PAGE. All the recombinant protein accumulated in the inclusion bodies. Purification of inclusion bodies, refolding and protein purification were all carried out as previously described [16] . Anti-HIV-1 scFv purification was carried out by immobilized-metal-affinity-chromatography (IMAC) according to the suppliers' protocol (Qiagen Biotech, Hilden Germany).
Specificity determination of recombinant scFv
To determine antibody specificity, both a strip immunoblot assay (SIA) and an immunofluorescence assay (IF) were used. In the SIA [17] , the binding specificity of the recombinant anti-HIV-1 scFv was tested with an HIV-1 strip (HIV-1 serum detection Kit, GBI Biotech Corporation, Beijing, China) according to the manufacturers' instructions. Briefly, HIV-1 antigen strips were incubated with 1 ml of recombinant scFv, or control parent mAb, at a concentration of 1 nM (all antibodies were diluted in PBS with 1% skimmed milk). Following overnight incubation at 4 ∞ C, the strips were then incubated with anti-His-Tag mAb. The AP-based detection was performed with the AP-labelled anti-murine or antihuman IgG antibodies. Bands were developed with nitroblue-tetrazolium-5-bromo-4-chloro-3-indolylphosphate (NBTBCIP) substrate (Sigma-Aldrich BRL, St Louis, USA). In the immuno-fluorescence assay, HeLa-Env cells were seeded onto chamber slides in 24-well plates at 1·0 ¥ 10 4 cells per well. After overnight incubation, cells were fixed using 4% paraformaldehyde in PBS and blocked with 3% BSA. After incubation with scFv, or its control parent mAb, cells were stained with anti-His-tag mAb and FITC-labelled rabbit anti-mouse IgG. The cover-slips were analysed by fluorescence microscopy and the data were recorded using a digital charge-coupled device camera.
Affinity determination of recombinant scFv
The expressed scFv and its parent antibody were tested for binding to gp120 using a sandwich ELISA as described previously [18] . Briefly, using a negative control of normal murine IgG, or a positive control (directly coated HIV-1 gp120 antigen), the microplates were coated with 100 m l serial dilutions of the scFv or its parent antibody set. After overnight incubation at 4 ∞ C, and blockage with 3% BSA, recombinant baculovirus-expressed monomeric gp120 (5 m g/ml) and HIV-1 antibody positive serum (1 : 1000 diluted) were added sequentially. After washing with PBS, the plates were incubated with HRP-conjugated goat anti-human IgG. HRP activity was analysed using an ophenylenediamine substrate (Sigma) at 0·4 mg/ml in substrate buffer. The optical density at 490 nm was measured after incubation at room temperature for 30 min.
HIV-1 neutralization assays
The HIV-1 neutralization assay was based on the infection of MT4 cells by primary isolates of HIV-1 in the presence, or absence, of scFv or its parent mAbs. This was followed by detection of the p24 antigen using ELISA to assess HIV-1 replication as described previously [19] . In brief, 1000 50% tissue culture infectious doses (TCID50) of cell-free virions were incubated with various dilutions of scFv, or its parent mAbs, prior to the addition of healthy MT4 cells. Murine IgG was used as a negative control. The antibody-virus mixture was incubated for 1 h at 37 ∞ C and an equal volume of MT4 cells (2 ¥ 10 5 /ml) was then added to each well and incubated in fresh RPMI 1640 growth medium. The calculated neutralization titres refer to the antibody concentration present during this incubation step. After 3-5 days of incubation, the cell culture supernatants were then tested for their p24 content in an antigen capture ELISA as recommended by the manufacturer (Organon Teknika, Boxtel, Netherlands).
Results
Amplification of VH and VL genes, and construction of the anti-HIV-1 scFv gene
The scFv gene was constructed using overlapping PCR (Fig. 1) , and its DNA sequence was analysed. As shown in Fig. 2 , the recombinant scFv102 fragment contains 705 base pairs and encodes 235 amino acid residues. The nucleotide and deduced amino-acid sequences of scFv were analysed using a BLAST search and ExPASy Proteomics tools on a World Wide Web Internet server (http://www.expasy.org/ tools). These sequences were compared with other published variable regions of immunoglobulins stored in the GenBank database. The deduced amino-acid sequences of the constructed scFv contained three loops corresponding to the complementary determining regions of the V H and V L regions and the amino-acid residues involved in the canonical structures. Sequencing results demonstrated that the recombinant scFv102 gene was correctly constructed and that the variable regions of heavy and light chains were productively rearranged with the linker sequence. This gene CCA GGT CAA GCT GCA GGA GTC AGG ACT GAA CTT GTG AGG CCA GGG 45
AAA CCA GGA AAT GCT CCT AGG CTC TTA ATA TCT GGT GCA ACC ACT 540
GCT ACT TAT TAC TGT CAA CAG TAT TGG AGT CCT CCG TAC ACG TTC
tightly controlled bacterial expression system. In our experiments, anti-HIV-1 gp120 scFv102 DNA was inserted into the T7-promoter-controlled bacterial expression vector pET28a and the resulting scFv was successfully over expressed within a few hours of IPTG induction. The expressed anti-HIV-1 gp120 scFv contained histidine residues as a C-terminal marker sequence to facilitate purification and detection. Total cell content, including both soluble and insoluble fractions, were analysed by SDS-PAGE and Western blotting. Figure 3 shows strong expression of an scFv-His fusion protein of about 29 kD and the amount of scFv produced was 6·8 g/l (38·5% of the total protein). Most of the expressed anti-HIV-1 gp120-scFv protein was located in the insoluble fraction. The scFv could not be detected in the soluble fraction, nor in the culture medium (data not shown). The insoluble scFv was further purified by denatured Ni-NTA chelating resin affinity purification. The eluted fractions were analysed by Western blotting. A single homogenous 29-kD scFv band was detected corresponding to the expected molecular mass of the desired protein.
Although the expressed scFv was produced mainly in insoluble form, active antibody was recovered by simple denaturation, refolding and dialysis. After chromatography purification and refolding, 6·5 mg of scFv102 (90% pure) was obtained from l l of E. coli cells.
Specificity of scFv and comparison with mAb
The antigen binding specificity of the expressed scFv was determined by the use of a SIA and by indirect IF. In the SIA, nitrocellulose strips coated with various kinds of HIV-1 synthetic peptides representing highly conserved regions of viral proteins, including HIV-1 surface gp120, trans-membrane gp41, core protein p24, matrix protein p17, were used to capture the antibodies to HIV-1. The synthetic-peptide-based strips used have a capture site for the results and also a procedural-control site to confirm the validity of the assay. A positive result is indicated by the formation of a red line. In this experiment, the binding specificity of scFv102 to recombinant gp120 was compared with that of the parent antibody (Fig. 4a) . A positive signal was observed for scFv102 and the parent anti-HIV-1 gp120 mAbs when detected directly with AP-coupled anti-mouse IgG. The strips tested using the negative control did not show a signal line, i.e. there are no false-positive results, and no increased background was observed. An indirect IF assay was developed using HeLa cells expressing recombinant HIV-1 gp120. The specificity of the expressed scFv102 for HIV-1 gp120 antigens was confirmed by IF. Both recombinant scFv and its parent antibody reacted with the fixed HeLa-Env cells, but not with the control HeLa cells (Fig. 4b) . Strong green fluorescence was observed in fixed HeLa-Env cells incubated both with the E. coliproduced scFv and its parent mAb. The intensity of the scFvinduced IF reaction was similar to that obtained with the native IgG from the hybridoma supernatant 102. No fluorescence was observed in the control Hela cell groups, or in the fractions obtained from nontransformed E. coli cells or when the anti-His-tag mAb were omitted.
Affinity determination
To evaluate the affinity of the recombinant single-chain antibody, the abilities of the expressed anti-HIV-1 gp120 scFv102 and its parent antibody, specific for HIV-1 antigens, were compared using a sandwich ELISA. The binding affinities of the scFv102 and its parent mAb were measured by further capture of the antigen using HIV-1 positive serum and anti-human IgG. Constants were calculated from the ELISA data by a comparison with the positive control (anti-HIV-1 serum was coated directly). Figure 5 shows the results of this assay. When E. coli -expressed scFvs. were used to coat ELISA plates, the OD 490 was similar to that obtained with the native IgG. No reaction occurred with a control of healthy murine IgG (OD 490 < 0·080), or when the HIV-1 gp120 antigen was replaced with PBS buffer (OD 490 < 0·055). In the quantitative sandwich ELISA, however, the serial dilutions (at the lower concentrations) of the single-chain antibody generated a weaker signal than the native mAb ( P < 0·05, t -test). This indicates that the binding affinity of scFv102 to HIV-1 gp120 is approximately 4-5-fold weaker than that of the parent antibody.
Antibody neutralization assays
To determine the potency of HIV-1 neutralization by scFv102, we compared its ability to inhibit infection of human MT4 T-lymphoid cells using a primary isolate of HIV-1 in comparison with its parent antibody (Fig. 6) . The results from the neutralization assays showed that treatment of acutely infected MT4 cells with scFv significantly inhibited viral-associated cytopathology and p24 antigen production ( P < 0·01). The expressed scFv conferred 90% inhibition Fig. 3 . Expression and purification of recombinant scFv 102. scFv 102 was induced using IPTG and could be purified by metal affinity chromatography (IMAC). Coomassie-blue-stained SDS-polyacrylamide gel analysis revealed hyperexpression and purification of scFv102. Lane 1 -protein molecular weight standards. Lane 2, total cell extract ( E. coli DE3/pET-scFv induced with IPTG); Lane 3, metal affinity column flowthrough; Lanes 4-6, column fractions from purification (50 mM imidazole wash); Lanes 7-8, purified scFv was visible in the peak fractions from the gradient (200 mM imidazole wash). [20] [21] [22] . However, because they are foreign proteins, murine sources of antibodies may provoke immune reactions, which reduce or eliminate their therapeutic efficiency and/or evoke allergic or hypersensitivity reactions in patients. Previously, we identified a novel murine mAb (102), which recognized the conserved CD4 binding region of HIV-1 gp120. To avoid a heterologous rejection reaction to the murine antibodies, we developed a modified singlechain antibody molecule that may be useful for immunodiagnosis and immunotherapy of HIV-1 infection. We prepared an scFv from the cDNA of a mAb specific for HIV-1 gp120, and expressed it in bacterial cells. This approach employed hybridoma and recombinant DNA technology to make the selection process more reliable than the commonly used phage-display technology. Although the latter approach is more convenient for the selection of human, or mouse antibody fragments from naive libraries without the need for animal immunization [23] , it produces scFv with a low solubility and a reduced binding affinity making it unsuitable for therapeutic use [24] . In our experiments, only those scFv composed of V H and V L cDNA segments from native immunoglobulins with high-avidity were selected to avoid the hypermutation of the CDR3 region. This strategy facilitated the construction of high affinity derivative antibodies [25] . Mammalian heavy and light chain immunoglobulins contain four conserved framework regions (FRs) adjacent to the three complementarity-determining regions. Sequence analysis showed that the scFv gene we constructed was replicated with high fidelity and that the variable regions of the heavy and light chains were effectively rearranged with a flexible linker. This gene structure was demonstrated to resemble the published pattern of recombinant murine resource FV molecules and the conformation of this gene was shown to have better affinity than that of the V L linker and V H gene structure [26] . It is worth stressing here that the linker sequence and the metal-binding insert locations in scFv were essential for retaining the paratope affinity. This was achieved using a standard 5-residue linker (G 4 S) 3 peptide to hinder dimerization. The hydrophilic properties of serine allow hydrogen bonding to the solvent, and the glycines provide the necessary flexibility [27, 28] .
Functional tests revealed that the specificities of this recombinant scFv and its parent native mAb were similar. However, the affinity of the recombinant scFv102 was a little weaker than that of the parent mAb. To explain this difference we must consider the fact that the single-chain antibody uses a peptide linker to flexibly connect its two domains, thus preventing dissociation of the two variable-region domains in physiological environments. The linker peptide may either distort, or not fully stabilize the precise conformation of the antigen-binding domain [29] . Besides that, the bivalency of the whole mAb IgG molecule provides another explanation for the results as it has been found that some single-chain antibodies have a 5-10-fold lower antigen binding affinity than the parent mAb. The weaker affinity is probably also due to the poor efficiency of refolding and the presence of the His-tag [30] . In a functional perturbation study, the scFv constructed could effectively recognize the conserved domains of HIV-1 gp120 and inhibit viral replication. It might have been expected that blocking this domain would effectively inhibit the binding of CD4 to gp120 and prevent the conformational changes which are necessary for HIV-1 infection. There is mounting evidence to suggest that several neutralization targets exist on the gp120 envelope, including the CD4 binding site (CD4BS), the variable V1, V2, and V3 loops, the chemokine receptor binding sites and the site which becomes better exposed following CD4 binding (CD4i epitopes) [31, 32] . These sites are all important for the inhibition of viral replication. The antibodies to the V2 and V3 regions are mainly isolated or type specific, while the antibodies directed against the CD4BS, or the CD4i epitopes are broadly neutralizing. In our experiments, we constructed a scFv directed against the epitope overlapping the CD4 binding site of gp120. The relative conservation of the structure observed in this region among different viral strains leads to the suggestion that this scFv could offer broad neutralization. Even though further experiments are needed to analyse the antiviral effect of our constructed scFv102 against various strains of HIV-1, the observed inhibition of replication of primary isolates of HIV-1(SF2) B subtypes gives a direct indication that the anti-HIV-1 scFv constructed may be a potential candidate for HIV-1 immunodiagnostics or immunotherapy.
